论文部分内容阅读
Mitsubishi化学公司到2000年将投资100亿日元(1.25亿美元)大规模扩大C4馏份衍生物生产能力。该公司希望1996年春天开始执行这一计划。这将有助于保持其在东亚地区上述衍生物市场上的主导地位,以及到2000年使上述产品的年销售额达到250亿日元(3.13亿美元)。计划大规模扩大生产能力的产品有:在Yokkaichi工厂的1,4-丁二醇(1-4BD)、四氢呋喃(THF)和聚四亚甲基乙二醇醚(PTMG);Mizushima工厂的马来酸酐(MA)、γ-丁内酯(GBC)和N-甲基吡咯烷酮(NMP)。此外,该公司计划在1997年或1997年后在海外新建一座1-4BD。亚洲地区1-4BD、THF、MA和其他C4馏份衍生物的需求正在迅速增长,日本国内的需求也在回升。
Mitsubishi Chemical Co., Ltd. will invest 10 billion yen (US$125 million) in large-scale production of C4 fraction derivatives by the year 2000. The company hopes to start implementing this plan in the spring of 1996. This will help maintain its dominance in the aforementioned derivatives market in East Asia, and by 2000, annual sales of these products will reach 25 billion yen (313 million US dollars). Products that are planned to expand their production capacity on a large scale include 1,4-butanediol (1-4BD), tetrahydrofuran (THF) and polytetramethylene glycol ether (PTMG) at the Yokkaichi factory; Malay of the Mizushima factory Anhydride (MA), γ-butyrolactone (GBC) and N-methylpyrrolidone (NMP). In addition, the company plans to build a new 1-4BD overseas after 1997 or 1997. Demand for derivatives of 1-4BD, THF, MA and other C4 fractions in Asia is growing rapidly, and domestic demand in Japan is also picking up.